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Background: Delayed-release dimethyl fumarate
(DR-DMF) has cytoprotective and antiinﬂammatory
properties and has recently been approved in the
United States as an oral treatment for relapsing forms
of multiple sclerosis. The most common adverse
events associated with DR-DMF are ﬂushing and
gastrointestinal (GI) events, the incidences of which
diminish over time.
Objective: The purpose of this study was to evaluate
the tolerability and pharmacokinetic (PK) proﬁle of
DR-DMF with or without concomitant acetylsalicylic
acid (aspirin), a cyclooxygenase inhibitor.
Methods: Healthy volunteers (N ¼ 56) were
randomized to receive different dosing regimens of
DR-DMF or matching placebo with or without
pretreatment with 325 mg aspirin for 4 days. Plasma
levels of the active metabolite monomethyl fumarate
were assessed on days 1 and 4. Flushing and GI events
were assessed using patient-reported scales. Potential
ﬂushing mediators were explored.
Results: DR-DMF showed a safety, tolerability,
and PK proﬁle consistent with previous clinical expe-
rience, with no evidence of accumulation. Pretreat-
ment with aspirin had no effect on the primary PK
parameters, AUC0–10h, or Cmax. Flushing severity,
assessed by 2 subject-reported rating scales, was
generally mild and was rated highest at the start of
treatment. Pretreatment with aspirin reduced ﬂushing
incidence and intensity without affecting GI events or1582the PK proﬁle of DR-DMF. In some DR-DMF–treated
individuals, plasma concentrations of a prostaglandin
D2 (PGD2) metabolite were increased.
Conclusions: In healthy volunteers, DR-DMF was
well tolerated over 4 days of dosing, with a PK proﬁle
consistent with that previously reported and no
evidence of accumulation. Aspirin pretreatment re-
duced the incidence and intensity of ﬂushing without
affecting GI events or the DR-DMF PK proﬁle.
Elevated levels of PGD2 in some DR-DMF–treated
individuals suggest that ﬂushing may be, at least in
part, prostaglandin mediated. ClinicalTrials.gov iden-
tiﬁer: ID: NCT01281111. (Clin Ther. 2013;35:1582–
1594)
& 2013 The Authors. Published by Elsevier, Inc.
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S.I. Sheikh et al.relapsing forms of multiple sclerosis (MS),1 a chronic
disease of the central nervous system that may cause
permanent disability.2,3 The pharmacodynamic effects of
DR-DMF appear to be mediated predominantly via
activation of the nuclear factor (E2-related factor 2)
(Nrf2) antioxidant response pathway, which up-
regulates key molecules that allow cells to respond
to inﬂammatory or oxidative stress4 by promoting
protective antiinﬂammatory and cytoprotective
responses. In a variety of preclinical models, activation
of the Nrf2 pathway has demonstrated neuro-
protection in vitro and in vivo.5
Previous pharmacokinetic (PK) studies of DR-DMF
demonstrated that DR-DMF is rapidly metabolized
presystemically to the primary metabolite mono-
methyl fumarate (MMF) and that MMF exposure is
dose-proportional with high intersubject variability.
After single ascending doses of DR-DMF (120, 240,
and 360 mg), mean (SD) Cmax (Cmax of MMF) were
0.58 (0.17), 1.43 (0.29), and 1.90 (0.57) μg/mL,
respectively, with corresponding MMF AUC of 1.21
(0.37), 2.41 (0.58), and 3.78 (1.11) μg  h/mL, respec-
tively (Biogen Idec data on ﬁle; Study IKP/ID 33).
There was no evidence of accumulation after multiple
doses (either 120 or 240 mg DR-DMF given TID
for 2 days) in a cross-over study, with MMF con-
centrations below detectable limits at the end of
both days 1 and 2 (Biogen Idec data on ﬁle; Study
FG-PK-03/04).
In 2 recently completed, 2-year, Phase III studies
in patients with MS, DEFINE (Efﬁcacy and Safety
of Oral BG-12 in Relapsing-Remitting Multiple
Sclerosis; NCT00420212) and CONFIRM (Efﬁcacy
and Safety Study of Oral BG-12 With Active Refer-
ence in Relapsing-Remitting Multiple Sclerosis;
NCT00451451), DR-DMF 240 mg given BID or
TID resulted in signiﬁcant improvements in clinical
and neuroradiologic measures of MS disease activity
accompanied by acceptable safety and tolerability
compared with placebo.6,7 The most commonly re-
ported adverse events (AEs) in the Phase III MS studies
were ﬂushing and gastrointestinal (GI) events (mild or
moderate for most patients).6,7
In general, the term “ﬂushing” describes temporary
symptoms occurring mainly on the face and neck,
including redness, itching, tingling, and warmth sen-
sation of the skin. Flushing may occur as a normal
physiologic response to increased temperature, exer-
cise, or consumption of spicy foods and in associationOctober 2013with various conditions (allergic reactions, carcinoid
tumors, and menopause), and medications (including
niacin and selective serotonin reuptake inhibitors).
Flushing is caused by vasodilation of small skin
capillaries and can be mediated by different molecules,
including histamine, bradykinin, serotonin, and pros-
taglandins.8–12
Although the mechanism underlying DR-DMF–
induced ﬂushing is not well understood, certain
features, such as a comparable clinical course and
timing, suggested that it may be similar to the niacin-
induced mechanism of ﬂushing. Flushing is a common
side effect of niacin therapy, and it usually subsides
with continued use.13 Several studies have shown that
niacin-induced ﬂushing is mediated via prostaglandin
(PG) release (including PGD2 and PGE2) from epider-
mal Langerhans cells11,12,14,15 and keratinocytes.16,17
If DR-DMF–induced ﬂushing were mediated by PG, a
known inhibitor of PG synthesis, aspirin (acetylsali-
cylic acid), would be expected to reduce the incidence
and/or intensity of ﬂushing. The present study was
designed to evaluate the tolerability and PK proﬁle of
DR-DMF after 4 days of dosing and to evaluate and
characterize ﬂushing and GI events with and without
325 mg aspirin given 30 minutes before DR-DMF
dosing.
METHODS
Study Design
This was a randomized, double-blind, placebo-
controlled study in healthy adult volunteers. A total
of 56 subjects were randomized; 8 groups of 6 subjects
were assigned to receive 4 days of treatment with DR-
DMF 240 mg BID, DR-DMF 240 mg TID, DR-DMF
360 mg BID, or placebo, with either aspirin 325 mg or
matching placebo administered 30 minutes before
each DR-DMF dose to allow sufﬁcient time for the
aspirin dose to begin to exert an effect. An additional
8 subjects were assigned to a modiﬁed dosing group
receiving DR-DMF 120 mg (6 subjects) or placebo (2
subjects) given 6 times daily (3 doses at hourly
intervals in the morning and a further 3 doses at
hourly intervals in the evening) (see Supplemental
Figure 1 in the online version at http://dx.doi.org/10.
1016/j.clinthera.2013.08.009). Here, we report the
detailed ﬁndings for the 240 mg BID and TID
dosing schedules since these correspond to the doses
evaluated in the Phase III studies of DR-DMF in
patients with MS6,7; results of the other dosing1583
Clinical Therapeuticsschedules can be found in Supplemental Tables I and
II and Supplemental Figures 2–5 in the online version
at http://dx.doi.org/10.1016/j.clinthera.2013.08.009.
Subjects were excluded if they had signs or symp-
toms of any major disease or known bacterial, viral,
or fungal infection. Subjects were also excluded if they
had a history of severe allergic or anaphylactic
reactions or intolerance to aspirin or nonsteroidal
antiinﬂammatory drugs. Treatment with any prescrip-
tion medication or vaccination in the previous month
or use of over-the-counter medication for the treat-
ment of allergy or GI complaints in the 14 days before
day 1 also led to exclusion. In addition, subjects were
excluded if they had consumed alcohol or undertaken
vigorous exercise in the 48 hours before day 1. The
use of hormonal contraceptives was allowed, provided
the dose and regimen were stable in the previous
28 days. Subjects satisfying the eligibility criteria were
randomized, and the ﬁrst dose of study drug was
administered after baseline assessments. Subjects con-
tinued to receive study drug according to their treat-
ment schedule for a total of 4 days. All treatments
were given immediately before a standardized meal.
Subjects remained in the study until after all day
5 assessments were completed, with a follow-up
assessment on day 11.
The study was conducted in accordance with the
protocol and principles of Good Clinical Practice and
the Declaration of Helsinki. The study protocol was
approved by the site’s institutional review board
before initiation, and written informed consent was
obtained from each subject before screening.
Study Subjects
This study included healthy adult volunteers. Eligi-
ble candidates were between 18 and 55 years of age
with a body mass index of 18–34 kg/m2. Female
subjects of child-bearing potential were required to
practice effective contraception during the study and
be willing and able to continue contraception for 30
days beyond their last dose of study treatment.
Study Treatments
DR-DMF was formulated as gelatin capsules con-
taining 120 mg DR-DMF enteric-coated microtablets.
The total daily dose of DR-DMF did not exceed 720
mg in any of the treatment groups. The DR-DMF
placebo group received capsules indistinguishable
from the active DR-DMF, which were administered1584in exactly the same way. In subjects assigned to
aspirin pretreatment, a ﬁlm-coated (but not enteric-
coated) tablet containing 325 mg aspirin was admin-
istered 30 minutes before DR-DMF or its matching
placebo. For subjects assigned to be pretreated with
aspirin placebo, the tablets received were indistin-
guishable from active aspirin and administered in
exactly the same way. Study staff and subjects were
blinded to the randomized treatments in the BID and
TID groups. The modiﬁed dosing regimen was un-
blinded to other groups but remained double-blinded
to treatment assignment (DR-DMF or placebo) within
the group. DR-DMF and matching placebo capsules
were manufactured by Biogen Idec (Cambridge, Mas-
sachusetts), and aspirin and matching placebo tablets
were manufactured by Time-Cap Labs Inc (Farm-
ingdale, New York).
Study Assessments
The PK proﬁle of DR-DMF was assessed by
measuring MMF concentrations in the plasma of
subjects at 30-minute intervals from baseline to 3 hours
post-dose, then hourly until 10 hours post-dose on
days 1 and 4. The concentration of MMF was
determined by high-pressure liquid chromatography
with tandem mass spectrometry (HPLC-MS/MS)-
MS/MS using fumaric acid monomethyl ester as the
internal standard.
Flushing severity was assessed by 2 validated
subject-reported measures, the Global Flushing Se-
verity Scale (GFSS) and the Flushing Severity Scale
(FSS). Both of these measures rate ﬂushing severity on
a scale of 0 to 10, where 0 ¼ no ﬂushing, 1–3 ¼ mild
ﬂushing, 4–6 ¼ moderate ﬂushing, 7–9 ¼ severe
ﬂushing, and 10 ¼ extreme ﬂushing. The GFSS18 is
a visual analog scale, which is part of the Flushing
Symptom Questionnaire (FSQ)19 and measures global
ﬂushing symptoms including redness, warmth, ting-
ling, and itching of the skin experienced over the
preceding 24 hours. Subjects completed the GFSS
immediately before the ﬁrst dose of study drug
(0 hours) on days 1 to 4, again on day 5 (24 hours
after the ﬁrst dose on day 4), and once more at follow-
up on day 11. Using the FSS, subjects rated their
overall ﬂushing and 4 items describing speciﬁc ﬂush-
ing symptoms (redness, warmth, tingling, and itching)
at the time of administration of the questionnaire. The
FSS is modiﬁed from the FSQ19 and was administered
at 30-minute intervals from baseline to 3 hours post-Volume 35 Number 10
S.I. Sheikh et al.dose, then hourly until 12 hours post-dose on days
1 through 4, and once on day 5 (24 hours after the
ﬁrst dose on day 4) to assess the nature and intensity
of subject-reported ﬂushing symptoms at various time
points. Subjects rated 5 items relating only to the
period since they last answered the questionnaire and/
or received the study drug.
Laser Doppler perfusion was used as an explor-
atory quantitative measure of facial skin perfusion
during ﬂushing. This technique uses noninvasive
imaging of superﬁcial tissue blood perfusion, recorded
as blood perfusion units on a relative units scale.20
Laser Doppler perfusion was measured at the same
16 time points as the FSS.
The severity of GI symptoms was assessed in a
similar manner to the ﬂushing assessments by means
of 2 subject-reported scales developed internally for
this speciﬁc purpose: the Overall GI Symptom Scale
(OGISS) and the Acute GI Symptom Scale (AGISS).
The OGISS and the AGISS use a similar 10-point
scoring scale, where 0 ¼ no GI symptoms, 1–3 ¼ mild
symptoms, 4–6 ¼ moderate symptoms, 7–9 ¼ severe
symptoms, and 10 ¼ extreme symptoms. The OGISS
is a visual analog scale that rates overall GI symptoms
(diarrhea, vomiting, nausea, bloating/gas, and stom-
ach pain) experienced over the preceding 24 hours.
Subjects completed the OGISS immediately before
receiving study drug on days 1 to 4, again on day 5,
and once more at follow-up on day 11. The AGISS is a
5-item questionnaire that measures subjects’ opinions
of overall digestive symptoms, nausea, stomach pain,
bloating/gas, and vomiting since they last answered
the questionnaire and/or received the study drug. The
AGISS was administered at the same time points as
those used for the FSS, over 12 hours on days 1 to 4
and once on day 5.
The potential importance of PGD2 in the ﬂushing
response was assessed by measuring the major metabo-
lites of PGD2 in plasma and urine. These metabolites
were measured because PGD2 is unstable with a very
short half-life. Levels of 9α,11β-PGF2 (a major metabo-
lite of PGD2 in plasma) were measured from the plasma
samples drawn on days 1 and 4 within 40 minutes
before the ﬁrst dose and after dosing at 0.5, 1, 2, 3, 4, 6,
8, 10, and 12 hours. The concentrations of 9α,11β-PGF2
were determined by gas chromatography–mass spectro-
scopy (GC-MS) using d4-8-iso-PGF2α as the internal
standard.21 GC-MS analysis of plasma samples showed
no chromatographic interference between 9α,11β-PGF2,October 2013PGF2α, and 8-iso-PGF2α. The major urinary metabolite
of PGD2 is 9α,11β-dihydroxy-15-oxo-2,3,18,19-tetra-
norprost-5-ene-1,20-dioic acid (PGD-M). The levels of
PGD-M in urine were assayed as previously de-
scribed,22 by GC-MS of pooled urine samples col-
lected for 8 hours on day 1, and between 0 and 8
hours on days 1 and 4. 18O-PGD-M was used as the
internal standard.
The potential role of histamine in the ﬂushing
response was also evaluated; plasma histamine
concentrations were determined by LC-MS from
samples collected at the same time as those for
PGD2 on days 1 and 4, using d4-histamine as the
internal standard.
Throughout the study, safety evaluations were
performed, including monitoring of AEs (nature,
timing, severity, and relationship to study treatment
as assessed by the investigator), concomitant medica-
tions, physical examinations, 12-lead electrocardio-
graphic monitoring, assessments of vital signs, and
common hematologic, biochemical, and urinary
parameters.
Statistical Analyses
The study was designed to provide safety, toler-
ability, and PK data from multiple doses of DR-DMF
and to provide a clinical assessment of the effective-
ness of aspirin in reducing DR-DMF–associated ﬂush-
ing. The sample size was not based on statistical
considerations. A sample size of 6 subjects per treat-
ment group was expected to provide an 80% con-
ﬁdence interval half width of 1.57 units, assuming
an SD of 3.0 units on the GFSS.
Noncompartmental analysis was used to derive PK
parameters, including AUC, Cmax, tmax, t½, and lag
time. Summary statistics, including number, mean,
SD, median, and range were calculated for continuous
parameters, and frequencies and percentages were
calculated for categorical parameters.
RESULTS
Study Subjects
A total of 56 healthy volunteers were enrolled, all
of whom received the study drug and completed the
study (see Supplemental Figure 1 in the online version
at http://dx.doi.org/10.1016/j.clinthera.2013.08.009).
Baseline demographics are presented in Table I. None
of the volunteers had any clinically signiﬁcant medical
histories.1585
Table I. Baseline demographic characteristics.
BID or TID Dosing Regimen Without Aspirin BID or TID Dosing With Aspirin
Placebo
(n ¼ 6)
DR-DMF 240 mg
BID (n ¼ 6)
DR-DMF 240 mg
TID (n ¼ 6)
Placebo
(n ¼ 6)
DR-DMF 240 mg
BID (n ¼ 6)
DR-DMF 240 mg
TID (n ¼ 6)
Age, y
Mean (SD) 32.0 (9.67) 34.8 (9.77) 25.7 (9.07) 31.2 (12.54) 33.2 (7.55) 23.3 (4.46)
Median 32.5 30.5 22.0 25.0 33.0 21.0
Range 21–47 26–50 19–43 20–50 23–43 20–30
Sex, no. (%)
Male 6 (100) 5 (83) 3 (50) 5 (83) 3 (50) 3 (50)
Female 0 1 (17) 3 (50) 1 (17) 3 (50) 3 (50)
BMI, kg/m2
Mean (SD) 23.83 (3.866) 25.72 (3.612) 25.02 (3.719) 24.17 (2.411) 26.42 (3.700) 25.88 (2.159)
Median 22.65 24.85 23.60 24.45 26.25 25.35
Range 20.3–30.2 22.1–30.8 21.1–31.4 20.7–27.7 22.4–30.8 23.0–28.7
BMI ¼ body mass index; DR-DMF ¼ delayed-release dimethyl fumarate.
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Figure 1. Mean plasma MMF concentrations over time. DR-DMF was administered for 4 days with and
without aspirin. Plasma MMF concentrations were measured on day 1 (left-hand panel) and day 4
(right-hand panel). Aspirin or aspirin-matching placebo was taken 30 minutes before each dose of
study drug. DR-DMF ¼ delayed-release dimethyl fumarate; MMF ¼ monomethyl fumarate.
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The MMF Cmax time proﬁles (on days 1 and 4) had
irregular shapes and displayed high interindividual
variability for all treatment groups (Figure 1).
Summary PK parameters derived by noncompart-
mental analysis are listed in Table II. Pretreatment
with aspirin had no apparent effect on the
concentration-time proﬁles of any group. Although
characterized by high interindividual variation, me-
dian parameters were similar on days 1 and 4 within
each treatment group. Values for tmax were consis-
tently higher with TID dosing compared with BID
dosing due to carryover of the exposure from the ﬁrst
dose at the time of the second dose, which was
administered 4 hours later. Values for the (AUC0–10h)
were dose proportional and t½ values were short andOctober 2013while the irregular shape and multiple peaks of the
individual concentration-time proﬁles made t½ difﬁ-
cult to interpret, results were consistent with the
known PK proﬁle of DR-DMF.
For all treatment groups, with the exception of the
modiﬁed dosing regimen, the predose plasma MMF
concentrations measured on day 4 in the majority of
subjects were either below the lower limit of quanti-
ﬁcation (LLOQ) or at very low values. In these cases,
the predose carryover of exposure from previous
doses did not exceed 2% of the subsequent maximum.
Consequently, the data indicated that there was no
accumulation of exposure with any of the regimens
studied. This was conﬁrmed by comparison of the
Cmax and AUC0–10h values on days 1 and 4 for each
dosing arm with and without aspirin (Table II). There1587
Table II. Summary of PK parameters.
Parameter
DR-DMF 240 mg BID DR-DMF 240 mg TID
Without Aspirin
(n ¼ 6)
With Aspirin
(n ¼ 6)
Without Aspirin
(n ¼ 6)
With Aspirin
(n ¼ 6)
AUC0–10h, h  ng/mL
Day 1 2800.0 (2190–4450) 3020.0 (1450–4210) 5075.0 (4010–9920) 5875.0 (5180–9050)
Day 4 2865.0 (2450–4290) 2590.0 (1640–4450) 5815.0 (3310–8260) 5885.0 (4460–9630)
Cmax, ng/mL
Day 1 1335.0 (1030–2000) 1625.0 (884–3250) 1935.0 (1250–4240) 1970.0 (1110–2740)
Day 4 1730.0 (1110–2800) 1135.0 (834–2210) 2050.0 (777–3950) 1995.0 (1770–2740)
tmax, h
Day 1 4.0 (2–8) 2.8 (1–4) 6.0 (4–8) 5.0 (4–8)
Day 4 3.0 (1–5) 3.5 (2–6) 5.5 (3–8) 3.5 (1–7)
t½, h
Day 1 0.81 (0.5–3.3) 0.59 (0.5–2.4) 0.85 (0.5–13.7) 0.81 (0.5–4.7)
Day 4 0.63 (0.5–1.4) 0.56 (0.4–0.9) 1.05 (0.7–1.8) 0.88 (0.6–59.7)
Lag time, h
Day 1 0.50 (0.0–3.0) 0.25 (0.0–2.0) 0.5 (0.0–2.0) 1.75 (0.0–2.0)
Day 4 0.25 (0.0–1.5) 0.25 (0.0–1.5) 1.0 (0.0–2.0) 1.00 (0.0–3.0)
Clinical Therapeuticswas no systematic increase in either of these
parameters over 4 days of dosing, nor were there
any systematic changes in time-dependent parameters,
such as t½, tmax, and lag time, over the 4 days,
indicating that the shape and extent of the exposure
did not change with multiple doses during any dosing
regimen. In addition, aspirin pretreatment had no
apparent effect on the PK proﬁle of DR-DMF.
Subject-Reported Flushing Outcomes
Figure 2 shows that mean GFSS scores, which
measured the overall severity of ﬂushing in the
preceding 24 hours, were low (r3.5, suggesting mild
symptoms). At follow-up on day 11 (7 days after the
last dose of DR-DMF), GFSS scores for all groups had
returned to the baseline value of zero. Mean GFSS
scores were generally lower in subjects receiving DR-
DMF who had been pretreated with 325 mg aspirin
than in subjects treated with DR-DMF alone.
Flushing severity was rated highest on day 2
(reﬂecting overall ﬂushing symptoms on the ﬁrst day
of dosing), when mean GFSS scores in the DR-DMF
alone groups ranged from 1.5 to 3.5 (mild). Pretreat-
ment with aspirin reduced the incidence and intensity
of ﬂushing in subjects who received DR-DMF, with1588mean ratings on the day of greatest severity (day 2)
ranging from 0.3 to 1.0. Scores for placebo groups
(with or without aspirin) remained low throughout
the treatment period.
Similar to the GFSS scores, mean FSS scores, which
measured acute ﬂushing, were generally low. FSS scores
for acute ﬂushing were generally highest between 1 and
5 hours post-dose on each day and appeared to
decrease over time. Again, pretreatment with aspirin
325 mg decreased the intensity of ﬂushing events in
subjects treated with DR-DMF (Figure 2), with mean
FSS ranging from 0 to 1.0 on day 1, and remained
below 1.0 thereafter. As with the GFSS, mean overall
FSS scores for placebo groups (with or without aspirin)
remained very low throughout the study.
Doppler perfusion proﬁles showed a high degree
of interindividual variability in percentage changes
from baseline; however, the magnitude of the response
was decreased by aspirin pretreatment (see Supple-
mental Figure 6 in the online version at http://dx.doi.
org/10.1016/j.clinthera.2013.08.009). Visual inspec-
tion of the mean Doppler perfusion proﬁles for
subjects treated with DR-DMF alone showed that the
peaks appeared to correspond to the times associated
with maximum plasma MMF exposure.Volume 35 Number 10
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Figure 2. Mean GFSS (severity of flushing in the previous 24 hours) and FSS (severity of acute flushing) scores
over time. In both of these subject-reported instruments, severity of flushing was scored on a 10-
point scale (0 ¼ no flushing, 1–3 ¼ mild flushing, 4–6 ¼ moderate flushing, 7–9 ¼ severe flushing,
and 10 ¼ extreme flushing). Because the GFSS measures flushing symptoms in the previous 24
hours, GFSS scores on day 2 reflect flushing severity on the first day of dosing. Although not shown
on the graph, day 11 values for all groups were zero. DR-DMF ¼ delayed-release dimethyl fumarate;
FSS ¼ Flushing Severity Scale; GFSS ¼ Global Flushing Severity Scale.
S.I. Sheikh et al.Subject-Reported Gastrointestinal Outcomes
Mean OGISS scores, which measured GI symptoms
over the preceding 24 hours, were low (r1.0) through-
out the study for all treatment groups and were
reﬂective of mild symptoms. There were no apparent
treatment- or dose-related differences in GI symptoms,
and aspirin did not appear to modify the incidence or
intensity of symptoms on this scale (Figure 3).October 2013As with the OGISS, mean AGISS scores, which
measured acute GI symptoms, were low (r2.0) for
all treatment groups and were reﬂective of mild
symptoms. There were no apparent treatment- or
dose-related differences in GI symptoms and pre-
treatment with aspirin did not appear to modify the
reporting of acute GI symptoms on this scale
(Figure 3).1589
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Figure 3. Mean OGISS (digestive system side effects in the previous 24 hours) and AGISS (overall digestive
system side effects since last assessment or study drug administration) scores over time. In both of
these subject-reported instruments, severity of symptoms was scored on a 10-point scale (0 ¼ no
symptoms, 1–3 ¼ mild symptoms, 4–6 ¼ moderate symptoms, 7–9 ¼ severe symptoms and 10 ¼
extreme symptoms). AGISS ¼ Acute Gastrointestinal Symptom Scale; DR-DMF ¼ delayed-release
dimethyl fumarate; OGISS ¼ Overall Gastrointestinal Symptom Scale.
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In subjects treated with DR-DMF alone, the median
plasma concentrations of 9α,11β-PGF2 were elevated
 2–4 hours after DR-DMF administration on day 1
(Figure 4). When measured again on day 4, the median
plasma concentrations of this metabolite were decreased.
Subjects treated with DR-DMF plus aspirin showed no
elevation in their median plasma concentrations of
9α,11β-PGF2 on either of the assessment days (Figure 4).
There was an elevation in the median levels of
PGD-M (a major urinary metabolite of PGD2) in urine
from baseline to day 1 in some subjects treated with1590DR-DMF alone, which returned to near baseline levels
by day 4 for all subjects (see Supplemental Figure 7 in
the online version at http://dx.doi.org/10.1016/j.
clinthera.2013.08.009). This elevation was not seen
in the placebo groups or in subjects treated with DR-
DMF plus aspirin.
Plasma concentrations of histamine were subject to
high interindividual variability and no elevations were
apparent in any of the study groups on either of the
assessment days. Many of the values for histamine
were below the LLOQ. There were no obvious differ-
ences in the median plasma concentration-timeVolume 35 Number 10
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Figure 4. Median plasma concentrations of 9α,11β-PGF2 during the study. Values below the LLOQ were
imputed as LLOQ/2. 9α,11β-PGF2 ¼ 9α,11β-prostaglandin F2; DR-DMF ¼ delayed-release dimethyl
fumarate; LLOQ ¼ lower limit of quantification.
S.I. Sheikh et al.proﬁles of histamine between subjects treated with
DR-DMF alone or those treated with DR-DMF plus
aspirin or those treated with placebo.
Safety
The incidence of AEs was higher in subjects receiv-
ing DR-DMF than in those receiving placebo; how-
ever, most AEs were assessed as mild-to-moderate inOctober 2013severity. As expected, the most common AEs were
ﬂushing and GI symptoms. The incidence of ﬂushing
was lower in subjects who received aspirin pretreat-
ment than in those who did not.
In the subjects dosed with DR-DMF 240 mg BID or
TID, ﬂushing AEs were reported for 5 of 6 and 6 of
6 subjects without aspirin pretreatment compared
with 3 of 6 and 4 of 6 subjects given aspirin,1591
Clinical Therapeuticsrespectively. Three of 6 subjects in the placebo alone
group and 2 of 6 subjects in the placebo plus aspirin
group also reported ﬂushing. For all treatment groups,
the incidence of ﬂushing events was highest on day 1
and decreased over time. Most subjects experienced
ﬂushing for 2 or 3 days, with only a few subjects
reporting ﬂushing on all 4 days of dosing. Median
times from most recent dose to ﬁrst ﬂushing AE with
and without aspirin pretreatment were 16 versus
80 minutes (placebo group), 50 versus 55 minutes
(DR-DMF 240 mg BID) and 123 versus 81 minutes
(DR-DMF 240 mg TID group), respectively.
Other AEs occurring more frequently in the
DR-DMF groups than in the placebo group were
those affecting the GI system: GI-related AEs were
reported for 0 of 6, 3 of 6, and 1 of 6 subjects
receiving placebo, DR-DMF 240 mg BID, and
DR-DMF 240 mg TID, respectively, in those groups
who received DR-DMF without aspirin pretreatment,
and 1 of 6, 2 of 6, and 1 of 6 subjects, respectively, of
the placebo, BID, and TID groups who received
aspirin pretreatment.
Safety evaluations revealed no remarkable abnor-
malities on physical examinations, and no clinically
signiﬁcant shifts from baseline in laboratory values,
vital signs, or electrocardiograms were noted. No
subjects withdrew from the study and there were no
serious AEs or deaths.
DISCUSSION
The primary aims of this study were to evaluate the
tolerability and PK proﬁles of multiple dosing regimens
of DR-DMF over 4 days of dosing. In this study,
DR-DMF was well tolerated with a PK and safety proﬁle
consistent with that reported in other studies.6,7,23,24
As seen previously, mean plasma MMF concen-
tration-time proﬁles for all treatment groups were
characterized by high interindividual variability and
irregular shape. Despite this variability, the median
AUC0–10h and Cmax estimates derived by noncompart-
mental analysis were generally dose-proportional and
consistent with values from previous studies of
DR-DMF administered as 240 mg BID and TID.
There was no accumulation of DR-DMF with multiple
doses in any of the dosing regimens in the present
study. Pretreatment with aspirin had no effect on the
primary PK parameters, AUC0–10h, or Cmax.
Consistent with other studies of DR-DMF using the
240 mg BID and TID dosing regimens,6,7,24 the most1592common AEs reported were mild-to-moderate ﬂushing
and GI symptoms. Flushing and GI AEs may potentially
impair tolerability and compliance; however, experience
from the Phase III MS studies shows that few patients
discontinue due to these AEs. In the present study, we
aimed to explore whether predosing with aspirin before
DR-DMF administration would affect ﬂushing and/or
GI events. We also explored the etiology of DR-DMF–
induced ﬂushing by investigating the role of potential
ﬂushing mediators, such as PGD2 and histamine.
Phase III studies showed that the incidence of
ﬂushing events was highest in the ﬁrst month of
dosing and decreased to placebo levels by the third
month.6,7 The present study was the ﬁrst to look at
ﬂushing events during the initial days of exposure to
DR-DMF. Although the incidence of ﬂushing ap-
peared to decrease gradually over 4 days of treatment,
this ﬁnding has to be seen in the context of the small
sample size; a larger study would be needed to conﬁrm
this observation. Pretreatment with 325 mg aspirin
reduced ﬂushing intensity and incidence in subjects
treated with DR-DMF, indicating that the ﬂushing
response may be mediated by PGs.
The ﬂushing observed with DR-DMF may be
mechanistically similar to the ﬂushing response seen
after the administration of niacin, which is mediated,
at least in part, by PGD2.
11,12 Indeed, in the present
study, plasma levels of 9α,11β-PGF2 (a major metab-
olite of PGD2 in plasma) somewhat mirrored the
pattern of ﬂushing symptoms in that they were
elevated on day 1 in subjects treated with DR-DMF
and decreased by day 4. In our study, histamine levels
were not elevated after treatment with DR-DMF,
suggesting that DR-DMF–induced ﬂushing was not
an allergic response. Interestingly, histamine does not
appear to be involved in niacin-associated ﬂushing, as
reported by Papaliodis et al.12 A detailed study in mice
revealed that 2 distinct epidermal cell types were
involved in niacin- and MMF-induced ﬂushing.17
Both Langerhans cells and keratinocytes express the
G protein–coupled receptor 109A (GPR109A), which
can be activated by both niacin and MMF.17 In
Langerhans cells, activation of GPR109A leads to
production of PGD2 and PGE2 by cyclooxygenase
(COX) 1, whereas in keratinocytes, activation of
GPR109A promotes synthesis of PGE2 via COX-2.
These respective pathways are suppressible by selec-
tive COX-1 or COX-2 inhibitors,17 suggesting that
aspirin, a nonselective COX inhibitor, interferes withVolume 35 Number 10
S.I. Sheikh et al.both of these mechanisms to reduce the ﬂushing
response induced by both niacin and MMF.
An increased incidence of GI events has been noted
with DR-DMF relative to placebo treatment over 24 or
96 weeks in previous clinical studies.6,7,24 In this 4-day
study, GI events were infrequent and mild; pretreat-
ment with aspirin did not alter the proﬁle of GI events,
and there was no apparent association between any of
the putative ﬂushing mediators and GI events.
Although the ﬁndings of this small study are
intriguing, particularly as they relate to the potential
mechanism of ﬂushing with DR-DMF, there are a
number of limitations. Given the small size of the
dosing arms, formal statistical comparisons among
treatment groups are not possible. In addition, the
relatively short duration of DR-DMF administration
(over 4 days) does not allow for analysis of the longer
term impact of aspirin on ﬂushing and GI events and
does not provide answers to questions such as whether
there is a reappearance of ﬂushing symptoms after
discontinuation of aspirin. Nevertheless, this study
provides valuable information that serves as a guide
for the design of ongoing and future studies. Cur-
rently, a longer term study evaluating the effects of
aspirin pretreatment on ﬂushing and GI events in
healthy volunteers receiving DR-DMF is ongoing.
CONCLUSIONS
In this study, we conﬁrmed previous ﬁndings that
DR-DMF administered as 240 mg BID or TID is well
tolerated by healthy volunteers and that there was no
accumulation of exposure over 4 days of treatment.
Pretreatment with 325 mg aspirin did not affect PK
parameters or the incidence of GI events but did
attenuate ﬂushing symptoms in subjects treated with
DR-DMF. This suggests that aspirin pretreatment may
mitigate ﬂushing events in subjects who experience
more intense DR-DMF–associated ﬂushing. The in-
cidence and severity of ﬂushing, with or without
aspirin, tended to diminish over a relatively brief time
frame, suggesting that a degree of tolerance to this
phenomenon may occur. This is evidenced by the
reduced plasma levels of 9α,11β-PGF2 comparing day
1 with day 4 of dosing in subjects treated with
DR-DMF alone and supports the theory that the
ﬂushing response to DR-DMF may, at least in part,
be mediated by PGD2. The relationship among
DR-DMF exposure, PG levels, and ﬂushing warrants
further investigation.October 2013ACKNOWLEDGMENTS
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Supplemental Figure 1. Consolidated Standards of Reporting Trials diagram. DR-DMF ¼ delayed-release
dimethyl fumarate. *Assignment to the modified dosing regimen group was
unblinded because of differences in the dosing regimen. However, treatment
assignment within this group (placebo or dimethyl fumarate) was blinded.
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Supplemental Figure 2. Mean plasma MMF concentrations over time. DR-DMF 360 mg BID (with and
without aspirin) and modified dosing regimens. Plasma MMF concentrations were
measured on day 1 (left-hand panel) and day 4 (right-hand panel). Aspirin or
aspirin-matching placebo was taken 30 minutes before each dose of study drug in
the BID group. The modified dosing regimen was administered as one 120-mg
capsule/hour for 3 consecutive hours in the morning and in the evening (total daily
dose 720 mg); the modified dose group did not receive aspirin. Note different y-axis
scales. DR-DMF ¼ delayed-release dimethyl fumarate; MMF ¼ monomethyl
fumarate.
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modified dosing regimens. In both of these subject-reported instruments, severity of
flushing was scored on a 10-point scale (0 ¼ no flushing, 1–3 ¼ mild flushing, 4–6 ¼
moderate flushing, 7–9 ¼ severe flushing, and 10 ¼ extreme flushing). The modified
dosing regimen was administered as one 120-mg capsule/hour for 3 consecutive
hours in the morning and in the evening (total daily dose 720 mg); the modified dose
group did not receive aspirin. Since the GFSS measures flushing symptoms in the
previous 24 hours, GFSS scores on day 2 reflect flushing severity on the first day of
dosing. DR-DMF ¼ delayed-release dimethyl fumarate; FSS ¼ Flushing Severity Scale;
GFSS ¼ Global Flushing Severity Scale.
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PGD-M ¼ 9α,11β-dihydroxy-15-oxo-2,3,18,19-tetranorprost-5-ene-1,20-dioic acid.
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Supplemental Table I. Baseline demographic characteristics of additional dosing groups and overall study population.
BID Dosing Without Aspirin BID Dosing With Aspirin Modiﬁed Dosing Regimen*
Study Total
(N ¼ 56)
Placebo
(n ¼ 6)
DR-DMF 360 mg
BID (n ¼ 6)
Placebo
(n ¼ 6)
DR-DMF 360 mg
BID (n ¼ 6)
Placebo
(n ¼ 2)
DR-DMF 120 mg
(n ¼ 6)
Age, y
Mean (SD) 32.0 (9.67) 27.7 (7.99) 31.2 (12.54) 37.8 (5.95) 30.5 (6.36) 37.8 (11.16) 31.5 (9.48)
Median 32.5 26.0 25.0 38.0 30.5 39.5 29.0
Range 21–47 21–43 20–50 29–46 26–35 20–49 19–50
Sex, no.(%)
Male 6 (100) 5 (83) 5 (83) 5 (83) 2 (100) 4 (67) 41 (73)
Female 0 1 (17) 1 (17) 1 (17) 0 2 (33) 15 (27)
BMI, kg/m2
Mean (SD) 23.83 (3.866) 24.27 (2.202) 24.17 (2.411) 27.02 (4.152) 27.20 (3.394) 24.82 (3.975) 25.31 (3.290)
Median 22.65 24.65 24.45 26.55 27.20 23.95 24.80
Range 20.3–30.2 20.5–27.0 20.7–27.7 22.1–33.2 24.8–29.6 21.2–31.5 20.3–33.2
BMI ¼ body mass index; DR-DMF ¼ delayed-release dimethyl fumarate; PK ¼ pharmacokinetic.
Note: The modiﬁed dosing regimen was intended to emulate an extended release formulation and was included in this study because PK modeling data suggest that
modiﬁed dosing may generate a higher median Cmax than current clinical regimens, while prolonging the median tmax.
*One 120-mg capsule per hour for 3 consecutive hours in the morning and in the evening (total daily dose 720 mg).
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Supplemental Table II. Summary of PK parameters of additional dosing groups.
DR-DMF 360 mg BID
Parameter Without Aspirin (n ¼ 6) With Aspirin (n ¼ 6) Modiﬁed Dosing Regimen*
AUC0–10, h  ng/mL
Day 1 4350.0 (2800–5450) 5180.0 (3650–8220) 4420.0 (3020–7260)
Day 4 4895.0 (2850–6150) 4055.0 (3470–6400) 4770.0 (3180–6620)
Cmax, ng/mL
Day1 1565.0 (1330–3580) 2780.0 (1060–3860) 3295.0 (1500–5330)
Day 4 2050.0 (890–4070) 1730.0 (1420–2320) 3495.0 (1220–3790)
tmax, h
Day 1 4.0 (3–5) 4.0 (2–5) 5.0 (5–5)
Day 4 2.8 (2–7) 4.5 (4–9) 5.0 (3–5)
t½, h
Day 1 0.54 (0.5–15.3) 0.75 (0.6–2.0) 1.01 (0.6–3.1)
Day 4 0.76 (0.5–1.1) 0.94 (0.7–1.1) 0.82 (0.5–5.3)
Lag time, h
Day 1 0.5 (0.0–1.5) 0.0 (0.0–0.5) 0.75 (0.0–4.0)
Day 4 0.0 (0.0–3.0) 0.5 (0.0–1.5) 0.00 (0.0–3.0)
DR-DMF ¼ delayed-release dimethyl fumarate; PK ¼ pharmacokinetic.
Data shown as median (range).
*One 120-mg capsule per hour for 3 consecutive hours in the morning and in the evening (total daily dose 720 mg).
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